Microbot Medical Inc. (NASDAQ:MBOT) Short Interest Update

Microbot Medical Inc. (NASDAQ:MBOT) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 374,800 shares, an increase of 27.5% from the May 31st total of 293,900 shares. Based on an average trading volume of 2,570,000 shares, the days-to-cover ratio is presently 0.1 days.

Microbot Medical Stock Performance

NASDAQ:MBOT opened at $1.01 on Tuesday. The stock has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.17. The company has a market cap of $14.54 million, a price-to-earnings ratio of -1.13 and a beta of 1.68. Microbot Medical has a fifty-two week low of $0.86 and a fifty-two week high of $2.97.

Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). Research analysts predict that Microbot Medical will post -0.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Microbot Medical in a research report on Monday, June 3rd.

Hedge Funds Weigh In On Microbot Medical

An institutional investor recently bought a new position in Microbot Medical stock. Armistice Capital LLC purchased a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 300,000 shares of the biotechnology company’s stock, valued at approximately $492,000. Armistice Capital LLC owned approximately 2.56% of Microbot Medical as of its most recent filing with the SEC. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.